ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2021
Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy.
Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Long-term alveolar-capillary diffusion impairments after severe SARS-CoV-2 pneumonia.Annals of medicine · 2025Article
- 24-Month assessment of respiratory function in patients hospitalized for severe SARS-CoV-2 pneumonia: a follow-up study.Internal and emergency medicine · 2025Article
- Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics.Biomedicines · 2025Review
- Immune responses in children with secondary infection of mycoplasma pneumoniae after COVID-19: focus on eosinophils and IgE.BMC infectious diseases · 2025Observational
- Treatment of Severe Asthma: Case Report of Fast Action of Mepolizumab in a Patient with Recent SARS-CoV-2 Infection.Life (Basel, Switzerland) · 2024Article
- Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.Biomedicines · 2023Article
- SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.The journal of allergy and clinical immunology. In practice · 2022Article
- COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.Allergy · 2022Article
- Eosinophils and eosinophilic immune dysfunction in health and disease.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Repurposing of Chemotherapeutics to Combat COVID-19.Current topics in medicinal chemistry · 2022Article
- Asthma and COVID-19: a dangerous liaison?Asthma research and practice · 2021Review
- Understanding and Managing Severe Asthma in the Context of COVID-19.ImmunoTargets and therapy · 2021Review
- Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.Frontiers in pharmacology · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.